Principal Financial Group
MACK

Principal Financial Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Principal Financial Group’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,613
Closed -$25K – 2283
2017
Q2 		$25K Buy
2,613
+75
+3% +$1.53K ﹤0.01% 2253
2017
Q1 		$62K Sell
2,538
-164
-6% -$4.1K ﹤0.01% 2169
2016
Q4 		$87K Hold
2,702
– – ﹤0.01% 2168
2016
Q3 		$135K Hold
2,702
– – ﹤0.01% 2081
2016
Q2 		$115K Buy
2,702
+128
+5% +$6.97K ﹤0.01% 2075
2016
Q1 		$169K Buy
2,574
+142
+6% +$7.41K ﹤0.01% 2042
2015
Q4 		$151K Buy
2,432
+64
+3% +$4.5K ﹤0.01% 2081
2015
Q3 		$159K Sell
2,368
-113
-5% -$9.22K ﹤0.01% 2058
2015
Q2 		$241K Buy
2,481
+120
+5% +$11.4K ﹤0.01% 2002
2015
Q1 		$220K Buy
2,361
+186
+9% +$15.8K ﹤0.01% 2004
2014
Q4 		$193K Sell
2,175
-27
-1% -$1.97K ﹤0.01% 2046
2014
Q3 		$152K Sell
2,202
-84
-4% -$4.49K ﹤0.01% 2072
2014
Q2 		$131K Buy
+2,286
New +$116K ﹤0.01% 2167
2013
Q4 		– Sell
-5,749
Closed -$172K – 2331
2013
Q3 		$172K Buy
+5,749
New +$201K ﹤0.01% 2144

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Principal Financial Group's MACK Position: Q3 2017 in Review

Principal Financial Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 2,613 shares — an estimated $25K sold.

Principal Financial Group first reported a position in MACK in Q3 2013 and held it in 14 quarters. The position peaked at $241K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Principal Financial Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Principal Financial Group sold 2,613 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $25K.
  • Principal Financial Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 14 quarters.
  • Principal Financial Group's Merrimack Pharmaceuticals, Inc. position peaked at $241K in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Principal Financial Group's 13F filing for Q3 2017, filed 2 Nov 2017.